Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hochberg, F. H.
Right arrow Articles by Pruitt, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hochberg, F. H.
Right arrow Articles by Pruitt, A.
NEUROLOGY 1980;30:907
© 1980 American Academy of Neurology

Assumptions in the radiotherapy of glioblastoma

Fred H. Hochberg, M. D. and Amy Pruitt, M. D.

From the Neurology Service and the Charles S. Kubik Laboratory of Neuropathology, Massachusetts General Hospital, Boston, MA.

In the light of advances in computerized tomography (CT), we have retrospectively evaluated the assumptions that underlie the radiation therapy of glioblastoma: (1) No neuroradiologic technique provides an accurate delineation of tumor bulk and location, (2) glioblastoma is commonly multicentric, and (3) a major source of therapeutic failure is recurrence beyond radiotherapy fields.

  1. CT scans, performed on glioblastoma patients within 2 months of postmortem examination, defined both gross and microscopic tumor extent (within a 2-cm margin) in all but 6 of 35 patients evaluated. The major source of error was subependymal spread (four patients).
  2. Multicentricity occurred in only 4% of untreated and 6% of treated (radiotherapy with or without chemotherapy) patients. All multicentric lesions were identified on CT scans.
  3. Serial CT scans on 42 patients revealed that glioblastoma recurred within a 2-cm margin of the primary site in 90%. Occurrences outside this margin were accurately delineated by CT in all instances.

Because most patients show recurrence within or in close proximity to the original site, current radiation doses would appear to be inadequate for therapy of the primary tumor. CT scan accuracy may permit smaller-field and higher-dose irradiation therapy for glioblastoma.

Address correspondence and reprint requests to Dr. Hochberg, Neurology Service, Massachusetts General Hospital, Boston, MA 02114.

Accepted for publication December 11, 1979.




This article has been cited by other articles:


Home page
 NEJMHome page
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, et al.
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Neurology, March 4, 2008; 70(10): 779 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Liu, J. N. Sarkaria, C. A. Petell, G. Paraskevakou, P. J. Zollman, M. Schroeder, B. Carlson, P. A. Decker, W. Wu, C. D. James, et al.
Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme
Clin. Cancer Res., December 1, 2007; 13(23): 7155 - 7165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kneifel, D. Cordier, S. Good, M. C.S. Ionescu, A. Ghaffari, S. Hofer, M. Kretzschmar, M. Tolnay, C. Apostolidis, B. Waser, et al.
Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P.
Clin. Cancer Res., June 15, 2006; 12(12): 3843 - 3850.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Reardon, J. A. Quinn, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al.
Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
J. Nucl. Med., June 1, 2006; 47(6): 912 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al.
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. E. Pelloski, A. Mahajan, M. Maor, E. L. Chang, S. Woo, M. Gilbert, H. Colman, H. Yang, A. Ledoux, H. Blair, et al.
YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma
Clin. Cancer Res., May 1, 2005; 11(9): 3326 - 3334.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K Miwa, J Shinoda, H Yano, A Okumura, T Iwama, T Nakashima, and N Sakai
Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study
J. Neurol. Neurosurg. Psychiatry, October 1, 2004; 75(10): 1457 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
D. A. Larson, J. M. Suplica, S. M. Chang, K. R. Lamborn, M. W. McDermott, P. K. Sneed, M. D Prados, W. M. Wara, M. K. Nicholas, and M. S. Berger
Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
Neuro-oncol, April 1, 2004; 6(2): 119 - 126.
[Abstract] [PDF]

Home page
 JCOHome page
A. Olivi, S. A. Grossman, S. Tatter, F. Barker, K. Judy, J. Olsen, J. Bruce, D. Hilt, J. Fisher, and S. Piantadosi
Dose Escalation of Carmustine in Surgically Implanted Polymers in Patients With Recurrent Malignant Glioma: A New Approaches to Brain Tumor Therapy CNS Consortium Trial
J. Clin. Oncol., May 1, 2003; 21(9): 1845 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. Westphal, D. C. Hilt, E. Bortey, P. Delavault, R. Olivares, P. C. Warnke, I. R. Whittle, J. Jaaskelainen, and Z. Ram
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
Neuro-oncol, April 1, 2003; 5(2): 79 - 88.
[Abstract] [PDF]

Home page
 JCOHome page
J. L. Chan, S. W. Lee, B. A. Fraass, D. P. Normolle, H. S. Greenberg, L. R. Junck, S. S. Gebarski, and H. M. Sandler
Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal Radiotherapy
J. Clin. Oncol., March 15, 2002; 20(6): 1635 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
G. Moonis, J. Liu, J. K. Udupa, and D. B. Hackney
Estimation of Tumor Volume with Fuzzy-Connectedness Segmentation of MR Images
AJNR Am. J. Neuroradiol., March 1, 2002; 23(3): 356 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. R. Miller, C. R. Williams, D. J. Buchsbaum, and G. Y. Gillespie
Intratumoral 5-Fluorouracil Produced by Cytosine Deaminase/5-Fluorocytosine Gene Therapy Is Effective for Experimental Human Glioblastomas
Cancer Res., February 1, 2002; 62(3): 773 - 780.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Wild-Bode, M. Weller, A. Rimner, J. Dichgans, and W. Wick
Sublethal Irradiation Promotes Migration and Invasiveness of Glioma Cells: Implications for Radiotherapy of Human Glioblastoma
Cancer Res., March 1, 2001; 61(6): 2744 - 2750.
[Abstract] [Full Text]

Home page
 Hum Exp ToxicolHome page
B Gonzalez, A Casaco, P Alvarez, M Leon, M Arteaga, A Leon, E Santana, A Bada, R Figueredo, R Hernandez, et al.
Radiotoxicity of h-R3 monoclonal antibody labeled with 188Re administered intracerebrally in rats
Human and Experimental Toxicology, December 1, 2000; 19(12): 684 - 692.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis
The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status
Neuro-oncol, July 1, 1999; 1(3): 196 - 203.
[Abstract] [PDF]

Home page
 The OncologistHome page
N. G. Avgeropoulos and T. T. Batchelor
New Treatment Strategies for Malignant Gliomas
Oncologist, June 1, 1999; 4(3): 209 - 224.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
P. Sampath, J. Hanes, F. DiMeco, B. M. Tyler, D. Brat, D. M. Pardoll, and H. Brem
Paracrine Immunotherapy with Interleukin-2 and Local Chemotherapy Is Synergistic in the Treatment of Experimental Brain Tumors
Cancer Res., May 1, 1999; 59(9): 2107 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. R. Shapiro
Current Therapy for Brain Tumors: Back to the Future
Arch Neurol, April 1, 1999; 56(4): 429 - 432.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. I. Rosenthal and E. Glatstein
We've Got a Treatment, but What's the Disease? : or A Brief History of Hypofractionation and its Relationship to Stereotactic Radiosurgery
Oncologist, February 1, 1996; 1(1): 1 - 7.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. C. Chamberlain, D. Barba, P. Kormanik, A. M. Berson, W. M. Saunders, and M. C. Shea
Concurrent Cisplatin Therapy and Iodine 125 Brachytherapy for Recurrent Malignant Brain Tumors
Arch Neurol, February 1, 1995; 52(2): 162 - 167.
[Abstract] [PDF]

Home page
 ScienceHome page
R. Martuza, A Malick, J. Markert, K. Ruffner, and D. Coen
Experimental therapy of human glioma by means of a genetically engineered virus mutant
Science, May 10, 1991; 252(5007): 854 - 856.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by AAN Enterprises, Inc.